Preoperative transhepatic portal vein embolization for impaired residual hepatic function in patients with obstructive jaundice

1997 ◽  
Vol 4 (4) ◽  
pp. 373-376 ◽  
Author(s):  
Masato Nagino ◽  
Yuji Nimura ◽  
Junichi Kamiya ◽  
Michio Kanai ◽  
Katsuhiko Uesaka ◽  
...  
2021 ◽  
pp. 1-10
Author(s):  
Zühre Uz ◽  
Bülent Ergin ◽  
Lucinda Shen ◽  
Krijn P. van Lienden ◽  
Fadi Rassam ◽  
...  

<b><i>Introduction:</i></b> The microvascular events following portal vein embolization (PVE) are poorly understood despite the pivotal role of the microcirculation in liver regeneration and tumor progression. We aimed to assess the changes in hepatic microvascular perfusion and neo-angiogenesis after experimental PVE. <b><i>Methods:</i></b> PVE of the cranial liver lobes was performed in 12 New Zealand White rabbits divided into 2 groups of permanent (P-PVE) and reversible PVE (R-PVE), respectively. Hepatobiliary scintigraphy and CT were used to evaluate hepatic function and volume. Hepatic microcirculation was assessed using a handheld vital microscope (Cytocam) to measure microvascular density (total vessel density; TVD) before PVE, right after PVE, and 20 min after PVE, as well as at 14 days (D14 post-PVE) and 35 days (D35 post-PVE). Additionally, on D35, microvascular PO<sub>2</sub> and liver parenchymal VEGF were assessed. <b><i>Results:</i></b> Eleven rabbits were included after PVE (R-PVE, <i>n</i> = 5; P-PVE, <i>n</i> = 6). TVD in the nonembo­lized (hypertrophic) lobes was higher than in the embolized (atrophic) lobes of the P-PVE group at D35 post-PVE (36.7 ± 7.2 vs. 23.4 ± 4.9 mm/mm<sup>2</sup>; <i>p</i> &#x3c; 0.05). In the R-PVE group, TVD in the nonembolized lobes was not increased at D35. Function and volume were increased in the nonembolized lobes of the P-PVE group compared to the embolized lobes, but not in the R-PVE group. Likewise, the mmicrovascular PO<sub>2</sub> and VEGF staining rate were higher in the nonembolized lobes of the P-PVE group at D35 post-PVE. <b><i>Discussion/Conclusion:</i></b> Successful volumetric and functional hypertrophy of the nonembolized lobe was accompanied by microvascular alterations featuring increased neo-angiogenesis, microvascular density, and microvascular oxygen pressure following P-PVE.


2017 ◽  
Vol 55 (05) ◽  
pp. e28-e56
Author(s):  
B Scheiner ◽  
P Stammet ◽  
S Pokorny ◽  
T Bucsics ◽  
P Schwabl ◽  
...  

2019 ◽  
Author(s):  
Shelly Brancatelli ◽  
Deb Van Nostran

2013 ◽  
Vol 37 (5) ◽  
pp. 1251-1258 ◽  
Author(s):  
Dominik Geisel ◽  
Maciej Malinowski ◽  
Maciej-Janusz Powerski ◽  
Joost Wüstefeld ◽  
Victoria Heller ◽  
...  

HPB ◽  
2021 ◽  
Vol 23 ◽  
pp. S46-S47
Author(s):  
M. Couto ◽  
F. Gianonne ◽  
B. Guiu ◽  
F. Navarro ◽  
F. Panaro

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 200
Author(s):  
Salah Khayat ◽  
Gianluca Cassese ◽  
François Quenet ◽  
Christophe Cassinotto ◽  
Eric Assenat ◽  
...  

Colorectal liver metastases (CRLM) are the major cause of death in patients with colorectal cancer (CRC). The cornerstone treatment of CRLM is surgical resection. Post-operative morbidity and mortality are mainly linked to an inadequate future liver remnant (FLR). Nowadays preoperative portal vein embolization (PVE) is the most widely performed technique to increase the size of the future liver remnant (FLR) before major hepatectomies. One method recently proposed to increase the FLR is liver venous deprivation (LVD), but its oncological impact is still unknown. The aim of this study is to report first short- and long-term oncological outcomes after LVD in patients undergoing right (or extended right) hepatectomy for CRLM. Seventeen consecutive patients undergoing LVD between July 2015 and May 2020 before an (extended) right hepatectomy were retrospectively analyzed from an institutional database. Post-operative and follow-up data were analyzed and reported. Primary outcomes were 1-year and 3-year overall survival (OS) and hepatic recurrence (HR). Postoperative complications occurred in 8 patients (47%). No deaths occurred after surgery. HR occurred in 9 patients (52.9%). 1-year and 3-year OS were 87% (95% confidence interval [CI]: ±16%) and 60.3%, respectively (95% CI: ±23%). Median Disease-Free Survival (DFS) was 6 months (CI 95%: 4.7–7.2). With all the limitations of a retrospective study with a small sample size, LVD showed similar oncological outcomes compared to literature reports for Portal Vein Embolization (PVE).


Sign in / Sign up

Export Citation Format

Share Document